• / Free eNewsletters & Magazine
  • / My Account
Home>Mylan jumps 15% premarket after FDA OK for MS drug

Mylan jumps 15% premarket after FDA OK for MS drug

Mylan jumps 15% premarket after FDA OK for MS drug

10/04/2017

Shares in Mylan NV (MYL) rose 15% in premarket action after the maker of generic drugs late Tuesday announced (http://www.prnewswire.com/news-releases/mylan-announces-us-fda-approval-of-first-generic-for-copaxone-40-mgml-3-times-a-week-and-may-be-eligible-for-180-day-exclusivity-300530551.html) that the Food and Drug Administration had approved its generic versions for Teva Pharmaceutical Industries Ltd.'s Copaxone, a drug for people with relapsing forms of multiple sclerosis. Teva's stock (TEVA) fell 9% in premarket trading.

-Victor Reklaitis; 415-439-6400; AskNewswires@dowjones.com

 

(END) Dow Jones Newswires

10-04-17 0632ET

Copyright (c) 2017 Dow Jones & Company, Inc.

1

©2017 Morningstar Advisor. All right reserved.